Immatics Reports Promising IMA401 Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 hours ago
0mins
Source: Newsfilter
- Significant Clinical Efficacy: IMA401 demonstrated a confirmed objective response rate (ORR) of 29% (4/14) and a disease control rate (DCR) of 64% (9/14) in head and neck cancer patients, with a median duration of response (mDOR) of 8.8 months, indicating its potential as a new treatment option for heavily pretreated patients.
- Good Tolerability: IMA401 showed favorable tolerability at the recommended Phase 2 dose (RP2D) with or without pembrolizumab, with the most common treatment-related adverse events being low-grade cytokine release syndrome (CRS) and lymphopenia, and no severe toxicities observed, supporting its broad combinability in treatment regimens.
- Combination Therapy Outlook: Immatics has initiated a clinical trial evaluating the combination of IMA401 and IMA402 in squamous cell non-small cell lung cancer (sqNSCLC), with initial data expected in 2027, as this dual-targeting strategy aims to cover over 90% of patients and enhance anti-tumor activity.
- Data Presentation Plans: Clinical data for IMA401 will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026, and published simultaneously in Nature Medicine, further enhancing the company's influence in the precision medicine field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMTX
Wall Street analysts forecast IMTX stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.450
Low
11.00
Averages
16.25
High
19.00
Current: 11.450
Low
11.00
Averages
16.25
High
19.00
About IMTX
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immatics Reports Promising IMA401 Clinical Data
- Significant Clinical Efficacy: IMA401 demonstrated a confirmed objective response rate (ORR) of 29% (4/14) and a disease control rate (DCR) of 64% (9/14) in head and neck cancer patients, with a median duration of response (mDOR) of 8.8 months, indicating its potential as a new treatment option for heavily pretreated patients.
- Good Tolerability: IMA401 showed favorable tolerability at the recommended Phase 2 dose (RP2D) with or without pembrolizumab, with the most common treatment-related adverse events being low-grade cytokine release syndrome (CRS) and lymphopenia, and no severe toxicities observed, supporting its broad combinability in treatment regimens.
- Combination Therapy Outlook: Immatics has initiated a clinical trial evaluating the combination of IMA401 and IMA402 in squamous cell non-small cell lung cancer (sqNSCLC), with initial data expected in 2027, as this dual-targeting strategy aims to cover over 90% of patients and enhance anti-tumor activity.
- Data Presentation Plans: Clinical data for IMA401 will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026, and published simultaneously in Nature Medicine, further enhancing the company's influence in the precision medicine field.
See More
Immatics Reports Q1 2023 Financial Results
- Financial Overview: Immatics reported a Q1 2023 GAAP EPS of -€0.43, indicating challenges in profitability and reflecting pressure in market competition.
- Revenue Decline: The company generated €7.61 million in revenue, a 59.0% year-over-year decrease, highlighting significant difficulties in sales and market demand that could impact future liquidity.
- Market Reaction: The poor financial performance may undermine investor confidence in Immatics, leading to increased stock price volatility and affecting the company's ability to secure funding in the biotechnology sector.
- Strategic Adjustments: Immatics is considering acquiring Anzu-Cel Floor to enhance market competitiveness through resource and technology integration, which, despite current financial challenges, could lay the groundwork for future growth.
See More
Immatics' PRAME T-Cell Therapy Shows Remarkable Efficacy
- Successful Case Treatment: At the Hopp Children's Cancer Center, a 17-year-old with nephroblastoma achieved significant tumor reduction and marked regression of liver, lung, and brain metastases after receiving Immatics' PRAME T-cell therapy, with ongoing remission at six months post-treatment, highlighting the therapy's potential in pediatric cancers.
- Clinical Data Presentation: The patient experienced a deep anti-tumor response three months post-treatment, with PET scans and MRIs showing significant regression across all lesions, and liquid biopsy monitoring indicated no tumor-derived DNA, confirming molecular remission and underscoring the efficacy of PRAME T-cell therapy.
- Safety Assessment: Reported adverse events included manageable cytokine release syndrome, which resolved with multi-modal anti-cytokine therapy and corticosteroids, and the patient was in excellent physical condition at the six-month follow-up, indicating the therapy's safety and tolerability.
- Future Development Directions: Immatics plans to conduct clinical studies in Heidelberg targeting pediatric patients with PRAME-positive relapsed or refractory solid tumors to further evaluate the potential of PRAME T-cell therapies, aiming to provide new treatment options for children facing severe diseases.
See More
Immatics Reports FY Earnings: Revenue and EPS Analysis
- Earnings Overview: Immatics reported a FY GAAP EPS of -€1.61, indicating challenges in profitability that may affect investor confidence and market perception.
- Revenue Performance: The company generated revenue of €48.2M, which, while showing growth, has not reversed the loss situation, highlighting the need for improved product commercialization in a competitive market.
- Market Reaction: Due to ongoing losses and failure to achieve profitability, the market remains cautious about Immatics' future prospects, potentially leading to increased stock price volatility and impacting the company's ability to raise funds.
- Strategic Transition: Immatics is working to transition its PRAME leader into commercial reality; despite financial challenges, successful commercialization could provide long-term growth potential for the company.
See More
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
See More
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
See More
Immatics Reports Promising IMA401 Clinical Data
- Significant Clinical Efficacy: IMA401 demonstrated a confirmed objective response rate (ORR) of 29% (4/14) and a disease control rate (DCR) of 64% (9/14) in head and neck cancer patients, with a median duration of response (mDOR) of 8.8 months, indicating its potential as a new treatment option for heavily pretreated patients.
- Good Tolerability: IMA401 showed favorable tolerability at the recommended Phase 2 dose (RP2D) with or without pembrolizumab, with the most common treatment-related adverse events being low-grade cytokine release syndrome (CRS) and lymphopenia, and no severe toxicities observed, supporting its broad combinability in treatment regimens.
- Combination Therapy Outlook: Immatics has initiated a clinical trial evaluating the combination of IMA401 and IMA402 in squamous cell non-small cell lung cancer (sqNSCLC), with initial data expected in 2027, as this dual-targeting strategy aims to cover over 90% of patients and enhance anti-tumor activity.
- Data Presentation Plans: Clinical data for IMA401 will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026, and published simultaneously in Nature Medicine, further enhancing the company's influence in the precision medicine field.
See More
Immatics Reports Q1 2023 Financial Results
- Financial Overview: Immatics reported a Q1 2023 GAAP EPS of -€0.43, indicating challenges in profitability and reflecting pressure in market competition.
- Revenue Decline: The company generated €7.61 million in revenue, a 59.0% year-over-year decrease, highlighting significant difficulties in sales and market demand that could impact future liquidity.
- Market Reaction: The poor financial performance may undermine investor confidence in Immatics, leading to increased stock price volatility and affecting the company's ability to secure funding in the biotechnology sector.
- Strategic Adjustments: Immatics is considering acquiring Anzu-Cel Floor to enhance market competitiveness through resource and technology integration, which, despite current financial challenges, could lay the groundwork for future growth.
See More
Immatics' PRAME T-Cell Therapy Shows Remarkable Efficacy
- Successful Case Treatment: At the Hopp Children's Cancer Center, a 17-year-old with nephroblastoma achieved significant tumor reduction and marked regression of liver, lung, and brain metastases after receiving Immatics' PRAME T-cell therapy, with ongoing remission at six months post-treatment, highlighting the therapy's potential in pediatric cancers.
- Clinical Data Presentation: The patient experienced a deep anti-tumor response three months post-treatment, with PET scans and MRIs showing significant regression across all lesions, and liquid biopsy monitoring indicated no tumor-derived DNA, confirming molecular remission and underscoring the efficacy of PRAME T-cell therapy.
- Safety Assessment: Reported adverse events included manageable cytokine release syndrome, which resolved with multi-modal anti-cytokine therapy and corticosteroids, and the patient was in excellent physical condition at the six-month follow-up, indicating the therapy's safety and tolerability.
- Future Development Directions: Immatics plans to conduct clinical studies in Heidelberg targeting pediatric patients with PRAME-positive relapsed or refractory solid tumors to further evaluate the potential of PRAME T-cell therapies, aiming to provide new treatment options for children facing severe diseases.
See More
Immatics Reports FY Earnings: Revenue and EPS Analysis
- Earnings Overview: Immatics reported a FY GAAP EPS of -€1.61, indicating challenges in profitability that may affect investor confidence and market perception.
- Revenue Performance: The company generated revenue of €48.2M, which, while showing growth, has not reversed the loss situation, highlighting the need for improved product commercialization in a competitive market.
- Market Reaction: Due to ongoing losses and failure to achieve profitability, the market remains cautious about Immatics' future prospects, potentially leading to increased stock price volatility and impacting the company's ability to raise funds.
- Strategic Transition: Immatics is working to transition its PRAME leader into commercial reality; despite financial challenges, successful commercialization could provide long-term growth potential for the company.
See More
Immatics Sells 12.5M Shares at $10 Each, Raising $125M
- Funding Scale: Immatics has announced the sale of 12,500,000 ordinary shares at $10 each, expected to raise $125 million, which will provide crucial funding for the company's clinical development initiatives.
- Underwriter Lineup: The offering is being managed by Jefferies, Leerink Partners, and Cantor, reflecting market confidence in Immatics' future growth and potentially enhancing its reputation in the biopharmaceutical sector.
- Transaction Timeline: The offering is expected to close on December 8, 2025, subject to customary closing conditions, allowing the company to quickly access funds to support its research projects.
- Market Reaction Expectations: This financing will bolster Immatics' research capabilities in precision targeting of PRAME, potentially enhancing its competitive position in cancer treatment, particularly in therapies targeting over 50 types of cancer.
See More
Xilio Therapeutics, Inc. (XLO) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.
Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.
Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.
See More
